SUPN stock icon

Supernus Pharmaceuticals
SUPN

$28.95
0.03%

Market Cap: 1.59B

 

About: Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Employees: 652

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

54% more call options, than puts

Call options by funds: $3.47M | Put options by funds: $2.26M

16% more capital invested

Capital invested by funds: $1.65B [Q4 2023] → $1.92B (+$268M) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 2 (+0) [Q1 2024]

1% less funds holding

Funds holding: 244 [Q4 2023] → 242 (-2) [Q1 2024]

6% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 32

1.43% less ownership

Funds ownership: 104.56% [Q4 2023] → 103.13% (-1.43%) [Q1 2024]

31% less repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 97

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$41
42%
upside
Avg. target
$41
42%
upside
High target
$41
42%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Piper Sandler
David Amsellem
42%upside
$41
Overweight
Maintained
28 Feb 2024

Financial journalist opinion